Stockscreener 앱 받기
32.74
4.33%
1.36
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Fed Watch: What is Mineralys Therapeutics Incs revenue forecast2025 Market Overview & Smart Swing Trading Alerts - baoquankhu1.vn
Activity Recap: Is EKSO a potential multi baggerAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 7,709 Shares of Stock - MarketBeat
David Malcom Rodman Sells 11,367 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Sell Signal: Is Mineralys Therapeutics Inc. part of any major index2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $529,618.32 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics MLYS officer sells $277k in stock By Investing.com - Investing.com South Africa
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $72,195.90 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $205,167.36 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) CFO Sells $345,762.12 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock - Investing.com
Mineralys Therapeutics CEO Congleton sells $529k in MLYS stock - Investing.com
Buybacks Report: Will Mineralys Therapeutics Inc outperform tech stocksQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Patterns Watch: Whats Mineralys Therapeutics Incs historical returnJuly 2025 Rallies & Safe Capital Investment Plans - baoquankhu1.vn
Mineralys Targets Sleep Apnea and Hypertension With Lorundrostat: What Investors Should Watch - TipRanks
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Unveiling a 54% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Insider Sell: CEO Jon Congleton Sells Shares of Mineralys Therap - GuruFocus
Discipline and Rules-Based Execution in MLYS Response - Stock Traders Daily
Trend Recap: Whats the RSI of Mineralys Therapeutics Inc stockJuly 2025 PostEarnings & Reliable Breakout Forecasts - baoquankhu1.vn
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - ADVFN
Will Mineralys Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Outlook & Risk Adjusted Buy/Sell Alerts - Улправда
Mineralys Therapeutics (MLYS) Stock Analysis Report | Financials & Insights - Benzinga España
Can Mineralys Therapeutics Inc. stock attract ESG capital inflowsEarnings Risk Summary & Weekly Breakout Watchlists - ulpravda.ru
Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 7%Here's What Happened - MarketBeat
Is Mineralys Therapeutics Inc. stock a contrarian buyJuly 2025 Breakouts & Verified Momentum Watchlists - Улправда
Why Mineralys Therapeutics Inc. stock could outperform in 2025Quarterly Growth Report & Free Fast Entry Momentum Trade Alerts - Улправда
Mineralys Flags Key Data Readouts as Lorundrostat Nears FDA Decision - MyChesCo
Mineralys Therapeutics, Inc.Common Stock (NQ: MLYS - FinancialContent
Mineralys Therapeutics Insider Sold Shares Worth $9,261,028, According to a Recent SEC Filing - marketscreener.com
Mineralys Therapeutics Sees Unusually High Options Volume (NASDAQ:MLYS) - MarketBeat
MLYSMineralys Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 70,037 Shares of Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $6,748,879.30 in Stock - MarketBeat
Mineralys Therapeutics CMO Sells Over $9 Million in Company Stock - TradingView — Track All Markets
Mineralys Therapeutics(MLYS.US) Officer Sells US$9.26 Million in Common Stock - 富途牛牛
Mineralys Therapeutics: Lorundrostat’s Broad Efficacy, Favorable Safety, and Upside Indications Support Buy Rating on MLYS - TipRanks
Mineralys Therapeutics filed NDA for lorundrostat to U.S. FDA in late 2025 - marketscreener.com
Mineralys updates lorundrostat program and upcoming data milestones - TipRanks
Mineralys Therapeutics, Inc. (MLYS) Investor Outlook: Analyzing a Potential 42.67% Upside in the Biotech Sector - DirectorsTalk Interviews
Mineralys Therapeutics, Inc. Provides Corporate Update and Announces NDA Filing - TradingView — Track All Markets
Mineralys Therapeutics Provides Corporate Update and - GlobeNewswire
Will Mineralys Therapeutics Inc. stock maintain dividend yield2026 world cup usa national team round of 32 midfield engines build up play match prediction statistical analysis - Улправда
Mineralys updates Lorundrostat program and upcoming data milestones - MSN
Is JAMA-Lauded Launch-HTN And FDA Feedback Altering The Investment Case For Mineralys Therapeutics (MLYS)? - Sahm
Is Mineralys Therapeutics Getting To The Heart Of Hypertension With Lorundrostat? - RTTNews
Nasdaq Moves: Is Mineralys Therapeutics Inc stock a safe investment in uncertain marketsJuly 2025 Outlook & Real-Time Volume Spike Alerts - moha.gov.vn
Behavioral Patterns of MLYS and Institutional Flows - Stock Traders Daily
Mineralys Therapeutics Earnings Notes - Trefis
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus - ts2.tech
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 3.4%What's Next? - MarketBeat
Oversold Conditions For Mineralys Therapeutics (MLYS) - Nasdaq
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring a 38% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Simplify Asset Management Inc. Takes Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Commit To Buy Mineralys Therapeutics At $22.50, Earn 16.1% Annualized Using Options - Nasdaq
Mineralys Therapeutics prices $175M stock offering - MSN
Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS) - Seeking Alpha
Swedbank AB Sells 84,500 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Voya Investment Management LLC Grows Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge - Yahoo Finance
4.73%
0.92%
자본화:
|
볼륨(24시간):